SEARCH

SEARCH BY CITATION

References

  • 1
    Rebolj M, Van Ballegooijen M, Berkers LM, Habbema D. Monitoring a national cancer prevention program: successful changes in cervical cancer screening in the Netherlands. Int J Cancer 2007;120:80612.
  • 2
    Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007;370:890907.
  • 3
    Ronco G, Segnan N, Giorgi-Rossi P, Zappa M, Casadei GP, Carozzi F, et al. Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J Natl Cancer Inst 2006;98:76574.
  • 4
    Bulkmans NW, Berkhof J, Rozendaal L, Van Kemenade FJ, Boeke AJ, Bulk S, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007;370:176472.
  • 5
    Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 2010;11:24957.
  • 6
    Naucler P, Ryd W, Tornberg S, Strand A, Wadell G, Elfgren K, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007;357:158997.
  • 7
    Kitchener HC, Almonte M, Thomson C, Wheeler P, Sargent A, Stoykova B, et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol 2009;10:67282.
  • 8
    Siebers AG, Klinkhamer PJ, Grefte JM, Massuger LF, Vedder JE, Beijers-Broos A, et al. Comparison of liquid-based cytology with conventional cytology for detection of cervical cancer precursors: a randomized controlled trial. JAMA 2009;302:175764.
  • 9
    Castle PE, Bulten J, Confortini M, Klinkhamer P, Pellegrini A, Siebers AG, et al. Age-specific patterns of unsatisfactory results for conventional Pap smears and liquid-based cytology: data from two randomised clinical trials. BJOG 2010;117:106773.
  • 10
    Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006;367:124755.
  • 11
    Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. N Engl J Med 2008;359:82132.
  • 12
    De Kok IM, Van Ballegooijen M, Habbema JD. Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands. J Natl Cancer Inst 2009;101:108392.
  • 13
    Jit M, Choi YH, Edmunds WJ. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 2008;337:a769.
  • 14
    Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 2003;290:7819.
  • 15
    Coupe VM, Van Ginkel J, De Melker HE, Snijders PJ, Meijer CJ, Berkhof J. HPV16/18 vaccination to prevent cervical cancer in The Netherlands: model-based cost-effectiveness. Int J Cancer 2009;124:9708.
  • 16
    Marra F, Cloutier K, Oteng B, Marra C, Ogilvie G. Effectiveness and cost effectiveness of human papillomavirus vaccine: a systematic review. Pharmacoeconomics 2009;27:12747.
  • 17
    Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: Joint European Cohort Study. BMJ 2008;337:a1754.
  • 18
    Kim JJ, Wright TC, Goldie SJ. Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy. J Natl Cancer Inst 2005;97:88895.
  • 19
    Van Ballegooijen M, Van Den Akker-Van Marle ME, Warmerdam PG, Meijer CJ, Walboomers JM, Habbema JD. Present evidence on the value of HPV testing for cervical cancer screening: a model-based exploration of the (cost-)effectiveness. Br J Cancer 1997;76:6517.
  • 20
    Van Den Akker-Van Marle ME, Van Ballegooijen M, Van Oortmarssen GJ, Boer R, Habbema JD. Cost-effectiveness of cervical cancer screening: comparison of screening policies. J Natl Cancer Inst 2002;94:193204.
  • 21
    Berkhof J, Coupe VM, Bogaards JA, Van Kemenade FJ, Helmerhorst T, Snijders PJ, et al. The health and economic effects of HPV DNA screening in the Netherlands. Int J Cancer 2010;127:214758.
  • 22
    Mittendorf T, Petry KU, Iftner T, Greiner W, Von Der Schulenburg JM. Economic evaluation of human papillomavirus screening in Germany. Eur J Health Econ 2003;4:20915.
  • 23
    Kim JJ, Ortendahl J, Goldie SJ. Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States. Ann Intern Med 2009;151:53845.
  • 24
    Chuck A. Cost-effectiveness of 21 alternative cervical cancer screening strategies. Value Health 2010;13:16979.
  • 25
    Mandelblatt JS, Lawrence WF, Womack SM, Jacobson D, Yi B, Hwang YT, et al. Benefits and costs of using HPV testing to screen for cervical cancer. JAMA 2002;287:237281.
  • 26
    Straughn JM Jr, Numnum TM, Rocconi RP, Leath CA Iii, Partridge EE. A cost-effectiveness analysis of screening strategies for cervical intraepithelial neoplasia. J Low Genit Tract Dis 2004;8:2804.
  • 27
    Maxwell GL, Carlson JW, Ochoa M, Krivak T, Rose GS, Myers ER. Costs and effectiveness of alternative strategies for cervical cancer screening in military beneficiaries. Obstet Gynecol 2002;100:7408.
  • 28
    Legood R, Gray A, Wolstenholme J, Moss S. Lifetime effects, costs, and cost effectiveness of testing for human papillomavirus to manage low grade cytological abnormalities: results of the NHS pilot studies. BMJ 2006;332:7985.
  • 29
    Goldie SJ, Kim JJ, Wright TC. Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. Obstet Gynecol 2004;103:61931.
  • 30
    Bistoletti P, Sennfalt K, Dillner J. Cost-effectiveness of primary cytology and HPV DNA cervical screening. Int J Cancer 2008;122:3726.
  • 31
    Muhlberger N, Sroczynski G, Esteban E, Mittendorf T, Miksad RA, Siebert U. Cost-effectiveness of primarily human papillomavirus-based cervical cancer screening in settings with currently established Pap screening: a systematic review commissioned by the German Federal Ministry of Health. Int J Technol Assess Health Care 2008 Spring;24:18492.
  • 32
    Sharma M, Ortendahl J, van der Ham E, Sy S, Kim J. Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in Thailand. BJOG 2012;119:16677.
  • 33
    Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006;119:1095101.
  • 34
    Dutch Society for Pathology (NVVP). Guideline Draft 2.0; Quality Assurance of Cytopathological Investigation of the Cervix [in Dutch]. Utrecht: Dutch Society for Pathology (NVVP), 2006.
  • 35
    Naucler P, Ryd W, Tornberg S, Strand A, Wadell G, Elfgren K, et al. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst 2009;101:8899.
  • 36
    Rebolj M, Bais AG, Van Ballegooijen M, Boer R, Meerding WJ, Helmerhorst TJ, et al. Human papillomavirus triage of women with persistent borderline or mildly dyskaryotic smears: comparison of costs and side effects of three alternative strategies. Int J Cancer 2007;121:152935.
  • 37
    Habbema JD, Van Oortmarssen GJ, Lubbe JT, Van Der Maas PJ. The MISCAN simulation program for the evaluation of screening for disease. Comput Methods Programs Biomed 1985;20:7993.
  • 38
    Statistics Netherlands (CBS). StatLine database. The Hague: Statistics Netherlands (CBS), 2011.
  • 39
    SIG (Information Centre for Health Care). Hospital Diagnosis Statistics 1963-1985. Utrecht: SIG, 1985.
  • 40
    Van Ballegooijen M. Effects and Costs of Cervical Cancer Screening. Rotterdam: Erasmus University, 1998.
  • 41
    Jacobs MV, Walboomers JM, Snijders PJ, Voorhorst FJ, Verheijen RH, Fransen-Daalmeijer N, et al. Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: the age-related patterns for high-risk and low-risk types. Int J Cancer 2000;87:2217.
  • 42
    Mccredie MR, Sharples KJ, Paul C, Baranyai J, Medley G, Jones RW, et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol 2008;9:42534.
  • 43
    Van Oortmarssen GJ, Habbema JD. Epidemiological evidence for age-dependent regression of pre-invasive cervical cancer. Br J Cancer 1991;64:55965.
  • 44
    De Bekker-Grob EW, De Kok IMCM, Bulten J, Van Rosmalen J, Vedder JEM, Arbyn M, et al. Is liquid-based cytology a cost-effective alternative in cervical cancer screening? Cancer Causes Control 2012; In Press.
  • 45
    Van Ballegooijen M, Rebolj M, Essink-Bot ML, Meerding WJ, Berkers LM, Habbema JDF. De Effecten en Kosten Van Het Bevolkingsonderzoek Naar Baarmoederhalskanker in Nederland na de Herstructurering. Rotterdam: Erasmus MC, afdeling Maatschappelijke Gezondheidszorg, 2006.
  • 46
    Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004;96:60415.
  • 47
    Karnon J, Peters J, Platt J, Chilcott J, Mcgoogan E, Brewer N. Liquid-based cytology in cervical screening: an updated rapid and systematic review and economic analysis. Health Technol Assess 2004;8:iii:178.
  • 48
    Sykes PH, Harker DY, Miller A, Whitehead M, Neal H, Wells JE, et al. A randomised comparison of SurePath liquid-based cytology and conventional smear cytology in a colposcopy clinic setting. BJOG 2008;115:137581.
  • 49
    College voor Zorgverzekeringen. Richtlijnen voor farmaco-economisch onderzoek, geactualiseerde versie. Diemen; College voor Zorgverzekeringen, 2006.
  • 50
    Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, et al. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst 2008;100:492501.
  • 51
    Clifford GM, Gallus S, Herrero R, Munoz N, Snijders PJ, Vaccarella S, et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 2005;366:9918.
  • 52
    Goldhaber-Fiebert JD, Stout NK, Salomon JA, Kuntz KM, Goldie SJ. Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination. J Natl Cancer Inst 2008;100:30820.
  • 53
    Kyndi M, Frederiksen K, Kruger Kjaer S. Cervical cancer incidence in Denmark over six decades (1943-2002). Acta Obstet Gynecol Scand 2006;85:10611.
  • 54
    Maucort-Boulch D, Franceschi S, Plummer M. International correlation between human papillomavirus prevalence and cervical cancer incidence. Cancer Epidemiol Biomarkers Prev 2008;17:71720.